CPDD 78th Annual Scientific Meeting Program

June 13, 2016 Fiesta
June 13, 2016 Fiesta
Monday, June 13, 2016
Symposium IV Monday,
COGNITIVE FUNCTION AS A NOVEL TREATMENT
TARGET FOR DRUG ADDICTION
6/8
10:15 - 12:15 PM
Chairs: Mehmet Sofuoglu and Kathleen Carroll
10:15 Psychostimulants as cognitive enhancers in cocaine addiction
Muhammad A. Parvaz, Icahn School of Medicine at Mount Sinai, New York, NY
10:40 Use of compensatory strategies in technological enhancement treatment for substance abusers
Efrat Aharonovich, Columbia University, New York, NY
11:05 Smart phones for smoking cessation: Cognitive bias modification for addiction
Andrew Waters, Uniformed Services University of the Health Sciences, Bethesda, MD
11:30 A placebo controlled trial of galantamine and CBT4CBT as a cognitive enhancement strategy
Kathleen Carroll, Yale University, West Haven, CT
11:55 DISCUSSANT: The promise of cognitive enhancement as a treatment for addictions
Mehmet Sofuoglu, Yale University School of Medicine, West Haven, CT
Oral Communications 3 Monday,
THE MAN WITH THE GOLDEN ARM: OPIOID TREATMENT
12
10:15 - 12:15 PM
Chairs: Charles Gorodetzky and Kelly E. Dunn
10:15 Pain severity and subsequent opioid use during buprenorphine-naloxone treatment of
prescription opioid- dependent patients with chronic pain
R. Weiss 1 , M. L. Griffin 3 , K. McDermott 2 , K. McHugh 4 , S. L. Karakula 2 , G. Fitzmaurice 4 ,
1
Harvard Medical School, Belmont, MA, 2 Alcohol and Drug Abuse Clinical Research
Program, McLean Hospital, Brookline, MA, 3 McLean Hospital/HMS, Belmont, MA, 4 McLean
Hospital/Harvard Medical School, Belmont, MA
10:30 The role of genetic polymorphisms on patient response to opioid use disorder therapy with
naltrexone and guanfacine
E. Blokhina 1 , E. Krupitsky 1,4 , A. Kibitov 3 , E. Verbitskaya 1 , T. Kosten 2 , D. A. Nielsen 2 ,
E. Zvartau 1 , 1 First Pavlov State Medical University, St. Petersburg, Russian Federation,
2
Baylor College of Medicine, Houston, TX, 3 Serbsky Federal Medical Research Centre
of Psychiatry and Narcology, Moscow, Russian Federation, 4 Bekhterev Research
Psychoneurological Institute, St. Petersburg, Russian Federation
10:45 Optimal minimum length of treatment in opioid-dependence with buprenorphine
V. Zah 1 , N. Matveev 1 , C. Chen 2 , J. Ruby 3 , 1 Health Economics, ZRx Outcomes Research
Inc., Mississauga, ON, Canada, 2 College of Pharmacy, University of New Mexico,
Albuquerque, NM, 3 Medical Affairs / HEOR, Indivior, Inc., Richmond, VA
11:00 Optimal prevention of relapse among opioid users: A 12-week randomized controlled trial of
extended-release naltrexone injections versus daily buprenorphine-naloxone
L. H. Tanum 1,3 , A. Opheim 2 , K. Solli 3 , K. Sharma-Haase 3 , Z. Latif 1 , N. Kunoe 3 , 1 R&D mental
health, Akershus University Hospital, Lorenskog (Oslo), Norway, 2 Department of addiction
medicine, Haukeland University Hospital, Bergen, Norway, 3 University of Oslo, Norwegian
Centre for Addiction Research, Oslo, Norway
9